The US Food and Drug Administration has turned down a new treatment for type 2 diabetes, dapagliflozin, the drug’s co-developers, AstraZeneca Plc and Bristol-Myers Squibb Company announced. The drug inhibits sodium-glucose transport proteins known as SGLT2.
